Inhibitex has begun enrollment in a Phase II clinical trial for Aurexis, an antibody being developed as a first-line therapy Staphylococcus aureus bloodstream infections in hospitalized patients.
The Phase II trial will enroll up to 60-patients in a multi-center, randomized, double-blind, placebo-controlled study. Hospitalized patients will be randomized to receive standard of care antibiotic therapy combined with either Aurexis or placebo.
Inhibitex says the Phase II trial is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of Aurexis, which the Atlanta-based company developed.
Last week, Inhibitex has filed a for an initial public offering reportedly worth as much as $86.3 million. The number of shares to be offered and at what price has not yet been determined, but the company will trade on the Nasdaq under the symbol “INHX.”